期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 11, 页码 1522-1526出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis736
关键词
-
资金
- US National Institutes of Health [R01 AI093316-01A1, 1P30AI094189-01A1]
- Bill & Melinda Gates Foundation [19790.01]
- Greenwall Faculty Scholars Program in Bioethics
In the last decade, many new rapid diagnostic tests for infectious diseases have been developed. In general, these new tests are developed with the intent to optimize feasibility and population health, not accuracy alone. However, unlike drugs or vaccines, diagnostic tests are evaluated and licensed on the basis of accuracy, not health impact (eg, reduced morbidity or mortality). Thus, these tests are sometimes recommended or scaled up for purposes of improving population health without randomized evidence that they do so. We highlight the importance of randomized trials to evaluate the health impact of novel diagnostics and note that such trials raise distinctive ethical challenges of equipoise, equity, and informed consent. We discuss the distinction between equipoise for patient-important outcomes versus diagnostic accuracy, the equity implications of evaluating health impact of diagnostics under routine conditions, and the importance of offering reasonable choices for informed consent in diagnostic trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据